Flumazenil
Flumazenil (Mazicon - Roche), a benzodiazepine receptor antagonist, has been approved by the US Food and Drug Administration to reverse the sedative effects of benzodiazepines after anesthesia, sedation for brief surgical or diagnostic procedures, or after benzodiazepine overdosage. The drug does not antagonize opioids, non-benzodiazepine sedatives, or anesthetic drugs....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Flumazenil
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 874
Article Code: 874b
Date: July 10, 1992
Volume: 34
Pages: 66-68
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 874
Article Code: 874b
Date: July 10, 1992
Volume: 34
Pages: 66-68
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)